PHARMACOBIOCHEMICAL EVALUATION OF RENOPROTECTIVE AGENTS IN CHRONIC KIDNEY DISEASE

Abstract

Chronic kidney disease is one of the leading causes of morbidity and mortality in the global world, and progressive loss of kidney function under usual clinical practice. Pharmacological interventions aimed at nephroprotection have become a significant part of disease management, but there are no real-life studies to support the relationship between pharmacological exposure and biochemical renal outcomes. To assess the pharmacobiochemical outcomes of renoprotective agents in patients with chronic kidney disease in a normal clinical setting. The medical records of 60 patients who had chronic kidney disease (35 males and 25 females) were used in a retrospective observational study. Pharmacological therapy data and regularly taken renal and biochemical parameters were already obtained. There were analyzes of changes in serum creatinine, estimated glomerular filtration rate, urea, proteinuria, and other biochemical markers to determine the pattern of renal functioning during treatment. A significant percentage of patients were linked with renal function parameter stabilization with the help of renoprotective therapy. There were small improvements in serum creatinine, and the estimated glomerular filtration rate deterioration was reduced in the follow-up. Positive changes in proteinuria and biochemical stability were recorded and there were no gender variations in response. The results validate the clinical utility of the pharmacobiochemical surveillance to evaluate the practical efficacy of renoprotective agents in chronic kidney disease and highlight the significance of continuous pharmacological treatment.